Recently, 2 large studies have shown that it was possible to predict the AML risk in healthy individuals years before diagnosis, based on the detection of CHIP.32,33 Interestingly, TP53, IDH1/2 and spliceosomal mutations (including SRSF2 and U2AF1) are associated with a higher risk of subsequent AML, in contrast with other mutations such as DNMT3A and TET2 mutations. Here, DNMT3A is linked to acute myeloid leukemia.